The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
Youth, Young Adults Have Worse Glycemic Control Than in the Past
Not all youth and young adults with diabetes are directly benefiting from the increased availability of diabetes technology, newer therapies, and the use of more aggressive glycemic targets.
Metformin Use Associated with Decreased PTSD Symptoms in Diabetic Veterans
An analysis of nearly 8k veterans has found use of metformin was associated with a reduction in PTSD symptoms.
Few RVO Patients Prescribed Anti-VEGF after Macular Edema Diagnosis
A new assessment shows about 60% of treatment-naive patients are not prescribed the most common drug class within 1 year of secondary edema.
Itamar Raz, MD: Impact of Dapagliflozin on Rapid Decline of eGFR
An analysis of the DECLARE-TIMI 58 trial suggests dapagliflozin use could reduce the risk of fast decline in eGFR.
Paolo Pozzilli, MD: Ladarixin, a CXCR1/2 inhibitor, in Type 1 Diabetes
Examining the results of MEX0114, a phase 2 trial evaluating the use of ladarixin in patients with new-onset type 1 diabetes.
Understanding Autoimmune Triggers Leading to Type 1 Diabetes in Children
An investigator provides an update on the TEDDY study.
Sirimon Reutrakul, MD: Using CPAP for Diabetes and Sleep Apnea
Sirimon Reutrakul, MD, discusses what providers should do based on the findings of a new study presented at ADA 2020.
Bruce Bode, MD: Impact of COVID-19 on Diabetes Care and Endocrinology
A leader in the field diabetic care, and endocrinology as a whole, Bruce Bode, MD, offers invaluable perspective on the impact of COVID-19 on clinical practice and major trials.
FDA Approves FreeStyle Libre 2 Integrated Continuous Glucose Monitor
The monitor is approved for children and adults 4 years and older with diabetes.
Meg Jardine, MBBS, PhD: Mediators and Pathways of Canagliflozin's CV Benefit
Results of a new study are diving deeper into potential mediators of the effects of canagliflozin on heart failure and CV death seen in CREDENCE.
Dapagliflozin Use Could Reduce Risk of Developing Type 2 Diabetes
A prespecified exploratory analysis suggests the SGLT2 inhibitor reduced the rate of new-onset diabetes by nearly a third.
Riccardo Perfetti, MD, PhD: AT-001 for Diabetic Complications
Chief Medical Officer of Applied Therapeutics discusses a study presented at ADA 2020 examining use of an aldose reductase inhibitor for diabetic complications.
Medicaid Expansion Positive For Minorities With Diabetic Foot Ulcerations
Patients living in states that chose to expand Medicaid coverage might be seeking care earlier to prevent major leg amputation.
Ildiko Lingvay, MD: Switching from Other GLP-1s to Once-Weekly Semaglutide
Results of the EXPERT study could help guide clinical decision making for GLP-1 RA-experienced patients.
Christopher Sorli, MD: Basal Insulin and GLP-1 for Type 2 Diabetes
Christopher Sorli, MD, describes the results of a study showing the need for simultaneous therapy rather than sequential.
Hui Shao, MD, PhD: Life Expectancy of Patients with Type 2 Diabetes Mellitus
Discussing a look at the current life expectancy of patients with T2DM with an assistant professor from the University of Florida’s College of Pharmacy.
Marc Penn, MD: Hepatic Directed Vesicle Insulin for Hypoglycemic Control
Discussing the results of a phase 2 study from Diasome examining use of HDV-insulin in type 1 diabetics.
Initial eGFR Decline with Empagliflozin Has No Impact on Reduction in CV Death
Silvio Inzucchi, MD, discusses an EMPA-REG OUTCOME analysis assessing the impact of empagliflozin in patients who experience an initial dip in eGFR.
Preventing Hypoglycemia, Hyperglycemia with Insulin and Glucagon Coadministration
Bruce Bode, MD, discusses the results of a proof-of-concept study examining insulin and glucagon coadministration to prevent hypoglycemia and hyperglycemia in type 1 diabetics.
REDUCE-IT DIABETES Strengthens Icosapent Ethyl's Safety, Efficacy Profile
Deepak Bhatt, MD, MPH, discusses the results of the latest REDUCE-IT analysis, titled REDUCE-IT DIABETES, presented at ADA 2020.
Dapagliflozin Effective Regardless of Background Diabetes Therapies
Kieran Docherty, MBChB, discusses the results of a DAPA-HF analysis he presented at ADA 2020.
Sensor-Based Glucose Monitor Reduces Diabetic Ketoacidosis Hospitalizations
Hospitalization rates decrease 52% for patients with type 1 diabetes and 47% for patients with type 2 diabetes.
Telehealth Platform Improves HbA1c Levels For Rural Type 2 Diabetes Patients
The intervention model can be used to help manage a variety of chronic diseases.
Canagliflozin Use Reduces Total Heart Failure Events by 36%
Discussing the effect of canagliflozin in patients with diabetes and chronic kidney disease with Meg Jardine, MBBS, PhD.
Patients With Diabetes Need Psychological Care
Survey findings highlight the psychological and psychosocial distress related to having diabetes.
Closed-Loop Tech Improves Daytime Blood Sugar Control for Type 1 Diabetes
More patients achieve international time in range consensus target of greater than 70% with the Advanced system.
Ildiko Lingvay, MD: Predictors of Gastrointestinal Events with Semaglutide
A recent analysis is examining potential factors associated with adverse gastrointestinal events in patients using semaglutide and whether it mitigates benefit.
Comparing Once-Weekly Semaglutide vs Daily Empagliflozin in Type 2 Diabetics
Discussing data from ADA 2020 with a professor of medicine at University of Texas Southwestern.
Vibeke Strand, MD: Important Rheumatology Data Coming Out of EULAR
Dr. Vibeke Strand discusses the relationship between COVID-19 and psoriatic arthritis.
Vibeke Strand, MD: Comorbidities Make Treating Psoriatic Arthritis Difficult
Dr. Vibeke Strand discusses how better treatment of psoriatic arthritis could yield better treatments for NASH.